Allisartan isoproxil improves endothelial function and vascular damage in patients with mild essential hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032332

Enrollment

Unknown

Registered

2020-04-26

Start date

2018-12-10

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

allisartan group:allisartan 240mg Qd

lifestyle group:lifestyle intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Mild essential hypertensive patients (BP ranged from 140/90mmHg to 159/99mmHg) 2. Aged from 25 to 75 years.

Exclusion criteria

Exclusion criteria: 1. Suffer from diabetes mellitus, coronary artery disease, peripheral vascular disease, acute or chronic liver diseases, renal insufficiency, hyperlipidemia, malignancies and infectious diseases; 2. Using non-steroid anti-inflammatory drugs, steroids, vasoactive agents treatment.

Design outcomes

Primary

Measure	Time frame
blood pressure;	—

Secondary

Measure	Time frame
flow-mediated vasodilatation;brachial-ankle pulse wave velocity;circulating endothelial microparticles;	—

Countries

China

Contacts

Public ContactTao Jun

The First Affiliated Hospital of Sun Yat-sen University

taojungz123@163.com+86 13922191609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026